Business Standard
Thursday, May 31, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

Pharma growth seen lower at 13% in 2009
Press Trust of India / Mumbai Mar 19, 2009, 13:23 IST

Indian pharma industry is now likely to clock 12-13 per cent growth in 2009 against earlier projections of 15 per cent due to the global economic meltdown, a research firm said.

"In 2009, the Indian pharma industry may see a growth of 12-13 per cent, as against our earlier forecast of 14-15 per cent, due to the macroeconomic condition that we are having," ORG IMS Research Managing Director Sameer Savkur said at a conference here.

 
Mumbai-based ORG IMS Research is a joint venture of AC Nielsen ORG-Marg and IMS Health, UK.

"Global pharma growth has been declining in the past five years. There is only a small impact on India. It will see double-digit topline growth," IMS Health UK Vice President Europe Graham Lewis said.

Lewis said there has been a significant amount of restructuring in the global pharmaceutical industry, with smaller companies running out of cash and bigger companies merging with each other.

The Indian pharma industry, which grew over 10 per cent last year, is likely to see a marginal one-to-two per cent spurt in growth in the next four to five years, Savkur said.

The industry witnessed a growth of only 10.2 per cent in 2008 due to some extraneous circumstances, he said.

He, however, termed the Indian pharmaceutical industry as "promising", and estimated its size to touch $30 billion by 2020.

Chronic therapy will continue to be a key growth driver, Savkur said, adding that companies are focusing on extra-urban markets as these contribute about 40 per cent to their turnover.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets end lower ahead of May F&O expiry
- Parsvnath posts Rs 23 cr loss in Q4
- Educomp net down 57% at Rs 61 cr in Jan-Mar qtr
- DLF Q4 net plunges 39% to Rs 211 cr
- Provogue Q4 net profit down 71% at Rs 1.81 cr
  Read Business news in 
- India's no. 1 Property Site. Click here to know more
- 
- "Discover The Power of One"
- Help a Child Achieve her. Click to know more
- The Best Seller is Also the No. 1 in Mileage. Click here
- Watch The Film Here. Click here to know more..
- Learn How One City is Running on FOOD SCRAPS.
- 1 billion in saving for Unilever without any tangles.
- A Brand New Server at a Price That Fits Your Budget. Click here
- One Partnership Endless Possibilities. Click here to know more
- Helping doctors detect diseases earlier, saving costs & extending lives.
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
- 2 Lac Apartments, 1 Lac House / Plots. Click here
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- Vodafone notice on arbitration premature: Govt
- Coal blocks for infrastructure projects get GoM nod
- Tata Motors skids as margins dip at JLR
- Wealthy clients turned tables on UBS and staff?
- Toyota looks at more small cars for India
 
 More  
Tax Shastra
  Now available at Special price
  Rs. 360/- Only

  Buy Now
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us